Zai Lab Ltd (NAS:ZLAB)

$ 20.78 1.38 (7.11%) Market Cap: 2.10 Bil Enterprise Value: 1.37 Bil PE Ratio: 0 PB Ratio: 2.65 GF Score: 69/100

Q4 2023 Zai Lab Ltd Earnings Call Transcript
Feb 28, 2024

$20.8 (-7.51%)

Earnings
Zai Lab Ltd at JPMorgan Healthcare Conference Transcript
Jan 08, 2024
Q3 2023 Zai Lab Ltd Earnings Call Transcript
Nov 08, 2023

$30.01 (+6.00%)

Earnings
Q2 2023 Zai Lab Ltd Earnings Call Transcript
Aug 08, 2023

$24.19 (-8.58%)

Earnings
Zai Lab Ltd Investor Day Transcript
Jun 20, 2023
Q1 2023 Zai Lab Ltd Earnings Call Transcript
May 10, 2023

$37.51 (+6.08%)

Earnings
Q4 2022 Zai Lab Ltd Earnings Call Transcript
Mar 02, 2023

$36.93 (-8.54%)

Earnings
Zai Lab Ltd at Citi BioTech C-Suite Fireside Chat Series (Virtual) Transcript
Feb 14, 2023
Zai Lab Ltd at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Q3 2022 Zai Lab Ltd Earnings Call Transcript
Nov 10, 2022

$30.39 (+6.37%)

Earnings
Zai Lab Ltd at Citi BioPharma Conference Transcript
Sep 08, 2022
Q2 2022 Zai Lab Ltd Earnings Call Transcript
Aug 10, 2022

$44.73 (-1.06%)

Earnings
Zai Lab Ltd at Goldman Sachs Global Healthcare Conference Transcript
Jun 16, 2022
Q1 2022 Zai Lab Ltd Earnings Call Transcript
May 11, 2022

$25.03 (-4.61%)

Earnings
Q4 2021 Zai Lab Ltd Earnings Call Transcript
Mar 02, 2022

$52.53 (-0.04%)

Earnings
Zai Lab Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 10, 2022
Q3 2021 Zai Lab Ltd Earnings Call Transcript
Nov 10, 2021

$87.82 (+1.30%)

Earnings
Zai Lab Ltd Topline POC Data Readout of ZL-1102 Corporate Call Transcript
Oct 21, 2021
Zai Lab Ltd R&D Day (Virtual) Transcript
Sep 22, 2021
Zai Lab Ltd at Citi BioPharma Conference (Virtual) Transcript
Sep 10, 2021
Q2 2021 Zai Lab Ltd Earnings Call Transcript
Aug 10, 2021

$149.76 (-2.77%)

Earnings
Zai Lab Ltd at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 08, 2021
Q1 2021 Zai Lab Ltd Earnings Call Transcript
May 10, 2021

$149.45 (-5.50%)

Earnings
Full Year 2020 Zai Lab Ltd Earnings Call Transcript
Mar 01, 2021

$162.02 (+9.83%)

Earnings
Zai Lab Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2021
Zai Lab Ltd at Citi BioPharma Conference (Virtual) Transcript
Sep 10, 2020
Half Year 2020 Zai Lab Ltd Earnings Call Transcript
Aug 13, 2020

$81.29 (+2.06%)

Earnings
Zai Lab Ltd at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 11, 2020
Zai Lab Ltd at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 13, 2020
Zai Lab Limited - Special Call Transcript
Apr 08, 2020
Q4 2019 Zai Lab Ltd Earnings Call Transcript
Mar 19, 2020

$49.64 (+2.03%)

Earnings
Zai Lab Ltd at JPMorgan Healthcare Conference Transcript
Jan 14, 2020
Q2 2019 Zai Lab Ltd Earnings Call Transcript
Sep 03, 2019

$32.54 (-0.21%)

Earnings
Zai Lab Ltd and Incyte Corp to Discuss the Collaboration and License Agreement for INCMGA0012 in Greater China Call Transcript
Jul 02, 2019
Zai Lab Ltd at Bank of America Merrill Lynch Health Care Conference Transcript
May 16, 2019
Zai Lab Ltd Corporate Analyst Meeting Transcript
Apr 30, 2019
Q4 2018 Zai Lab Ltd Earnings Call Transcript
Mar 07, 2019

$28.55 (+2.48%)

Earnings

Zai Lab Ltd at JPMorgan Healthcare Conference Transcript

Jan 14, 2020 / 10:30PM GMT

Release Date Price: $48.14 (+10.62%)

Transcript

Anupam Rama

JP Morgan Chase & Co, Research Division - VP and Analyst

We'll go ahead and get started. Yes, so we're getting started with this presentation. Welcome, everybody, to the Tuesday afternoon session of the 2020 JPMorgan Health Care Conference. My name is Anupam Rama. I am one of the senior biotech analyst here at JPMorgan. I'm joined by Matt Bannon and Tessa Romero from the team. Our next presenting company is Zai Lab, and presenting on behalf of the company, we have CEO, Samantha Du. Samantha?

Ying Du

Zai Lab Limited - Founder, Chairman & CEO

Thank you, Anupam. And thank you, everyone, for coming. Can you hear me better? Should I yell? I will try. And I'd like to start the company presentation with the slide and about our recent approval. We recently have ZEJULA second line approved in Mainland China in December 27, 2019. This is actually a very major event because this really transformed Zai Lab from a development stage company into a fully commercial, fully integrated, not just -- not only in Taiwan, not in Hong Kong, Macao, but also in

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.